| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 57.7 | 52.7 |
| Profit before tax | -0.5 | 0.1 |
| Net income | -0.6 | -0.0 |
| EPS (diluted, $ a share) | $-0.00 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +9.5% |
|---|---|
| Operating margin | 0.7% |
10-Q filed with the SEC, NASDAQ: CERS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cerus Corp: key numbers
- Share price
- $1.86Close, Nov 16
- Market cap
- $376M
- Shares outstanding
- 201.95MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cerus Corp
All →Cerus Earnings Call: Key Takeaways
Cerus delivered 10% revenue growth and positive Phase III Redis results, though regulatory timelines for the INT200 and CE Mark red cells have shifted later.
- Call
- Nov 2, 2026, 4:30 PM ET
Cerus Financial Results
Cerus Corporation reported Q3 2026 total revenue of $64.0 million, driven by 10% year-over-year growth in product revenue to $57.7 million. The company also announced positive topline Phase 3 results for its INTERCEPT Blood System for red blood cells and generated $3.0 million in operating cash flow during the quarter.
- Term
- Q3 2026
“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care.”
Vivek Jayaraman, Cerus’s president and chief executive officer